Miguel Villalona-Calero

Miguel Villalona-Calero

UNVERIFIED PROFILE

Are you Miguel Villalona-Calero?   Register this Author

Register author
Miguel Villalona-Calero

Miguel Villalona-Calero

Publications by authors named "Miguel Villalona-Calero"

Are you Miguel Villalona-Calero?   Register this Author

82Publications

2001Reads

15Profile Views

Type of TP53 mutation influences oncogenic potential and spectrum of associated K-ras mutations in lung-specific transgenic mice.

Int J Cancer 2019 Nov 13;145(9):2418-2426. Epub 2019 Apr 13.

Department of Human & Molecular Genetics, Herbert Wertheim College of Medicine, The Florida International University, Miami, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32279DOI Listing
November 2019

Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer.

Clin Lung Cancer 2018 11 22;19(6):e893-e900. Epub 2018 Aug 22.

Division of Medical Oncology, Ohio State University Wexner Medical Center, James Cancer Hospital and Solove Research Institute, Columbus, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.08.008DOI Listing
November 2018

EML4-ALK Rearrangement and Its Therapeutic Implications in Inflammatory Myofibroblastic Tumors.

Oncologist 2018 10 8;23(10):1127-1132. Epub 2018 May 8.

Miami Cancer Institute at Baptist Health South Florida, Miami, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263129PMC
October 2018

Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.

J Natl Cancer Inst 2016 Jul 4;108(7). Epub 2016 Feb 4.

Divisions of Medical Oncology (MAVC, WD, JR, ML, TBS) and Clinical Cancer Genetics (JAW), Department of Pathology (WZ, KS), Comprehensive Cancer Center (MAVC, WD, LJS, JT, TBS, CT), and Center for Biostatistics (LX), The Ohio State University , Columbus, OH ; Lombardi Cancer Center, Georgetown University , Washington, DC (JM); National Cancer Institute , Bethesda, MD (JJ, AC).

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/108/7/djv437.full.pdf
Web Search
http://jnci.oxfordjournals.org/lookup/doi/10.1093/jnci/djv43
Publisher Site
http://dx.doi.org/10.1093/jnci/djv437DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948564PMC
July 2016

Rad51C-ATXN7 fusion gene expression in colorectal tumors.

Mol Cancer 2016 06 13;15(1):47. Epub 2016 Jun 13.

Comprehensive Cancer Center, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12943-016-0527-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906819PMC
June 2016

Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

J Clin Oncol 2016 Mar 4;34(9):987-1011. Epub 2016 Feb 4.

Don S. Dizon, Massachusetts General Hospital, Boston; Erica Mayer, Dana-Farber Cancer Institute, Boston, MA; Lada Krilov and Richard Schilsky, American Society of Clinical Oncology, Alexandria, VA; Ezra Cohen, University of California San Diego, San Diego; Patricia A. Ganz, University of California Los Angeles, Los Angeles; Sumanta Kumar Pal, City of Hope Comprehensive Cancer Center, Duarte, CA; Tara Gangadhar, University of Pennsylvania; Stephen Hunger, Children's Hospital Center of Philadelphia, Philadelphia, PA; Thomas A. Hensing, University of Chicago, Evanston, IL; Smitha S. Krishnamurthi, Case Western Reserve University, Cleveland, OH; Andrew B. Lassman and Gary K. Schwartz, Columbia University; David R. Spriggs, Memorial Sloan Kettering Cancer Center; Gina Villani, Ralph Lauren Center for Cancer Care and Prevention, New York, NY; Merry Jennifer Markham, University of Florida, Gainesville; Miguel Angel Villalona-Calero, Miami Cancer Institute, Miami, FL; Michael Neuss, Vanderbilt-Ingram Cancer Center, Nashville, TN; Lisa C. Richardson, Centers for Disease Control and Prevention, Atlanta, GA; and Gregory Masters, Helen F. Graham Cancer Center and Research Institute, Newark, DE.

View Article

Download full-text PDF

Source
http://news.medlive.cn/uploadfile/20160205/14546422512856.pd
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.65.8427
Publisher Site
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075244PMC
http://dx.doi.org/10.1200/JCO.2015.65.8427DOI Listing
March 2016

Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary.

Cancer Chemother Pharmacol 2015 Nov 28;76(5):1005-12. Epub 2015 Sep 28.

Richard Solove Research Institute, The Ohio State University Comprehensive Cancer Center-James Cancer Hospital, 320 W 10th Avenue, Columbus, OH, 43221, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2877-6DOI Listing
November 2015

Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer.

Sci Rep 2015 Jul 10;5:12122. Epub 2015 Jul 10.

Divison of Medical Oncology, Ohio State University Comprehensive Cancer Center, 300 W 10th Ave, Columbus, OH 43210.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep12122DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894406PMC
July 2015

Overexpression of Rad51C splice variants in colorectal tumors.

Oncotarget 2015 Apr;6(11):8777-87

Comprehensive Cancer Center, The Ohio State University College of Medicine and Public Health, Columbus, Ohio, U.S.A.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496183PMC
http://dx.doi.org/10.18632/oncotarget.3209DOI Listing
April 2015

A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.

Mol Cancer Ther 2015 Feb 10;14(2):461-9. Epub 2014 Dec 10.

Division of Medical Oncology and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-14-0431DOI Listing
February 2015

Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer.

Front Oncol 2014 19;4:368. Epub 2014 Dec 19.

Comprehensive Cancer Center, The Ohio State University College of Medicine and Public Health , Columbus, OH , USA ; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine and Public Health , Columbus, OH , USA ; Department of Pharmacology, The Ohio State University College of Medicine and Public Health , Columbus, OH , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2014.00368DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271581PMC
January 2015

From single-gene to multiplex analysis in lung cancer, challenges and accomplishments: a review of a single institution's experience.

Lung Cancer Manag 2014 Aug;4(3):315-324

Departments of Internal Medicine & Pathology, The Ohio State University, 320 W, 10th Avenue, Columbus, OH 43210, USA ; Comprehensive Cancer Center, The Ohio State University, 320 W, 10th Avenue, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/lmt.14.23DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286371PMC
August 2014

CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.

J Thorac Oncol 2014 Feb;9(2):214-21

*Department of Thoracic Oncology, Massachusetts General Hospital, Boston, Massachusetts; †Department of Oncology, Alliance Statistics and Data Center, Duke University Medical Center, Durham, North Carolina; ‡Department of Oncology, Ohio State University Medical Center, Columbus, Ohio; §Department of Oncology, University of North Carolina, Chapel Hill, North Carolina; ‖Department of Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; ¶Department of Oncology, Kinston Medical Specialists, P.A., Kinston, North Carolina; #Department of Oncology, University of Chicago, Chicago, Illinois; and **Department of Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000071DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284815PMC
February 2014

Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors.

Diagn Pathol 2013 Dec 10;8:201. Epub 2013 Dec 10.

Department of Pathology, The Wexner Medical Center at the Ohio State University, 410 W, 10th Avenue, Columbus, OH, 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1746-1596-8-201DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933389PMC
December 2013

Case of sorafenib-induced thyroid storm.

J Clin Oncol 2013 Jun 22;31(16):e262-4. Epub 2013 Apr 22.

Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.46.7142DOI Listing
June 2013

Inhibition of Ras-Effector Interaction by Cyclic Peptides.

Medchemcomm 2013 Feb;4(2):378-382

Department of Chemistry and Biochemistry, The Ohio State University, 100 West 18 Avenue, Columbus, OH 43210, U. S. A. ; Tel: 614-688-4068.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/C2MD20329DDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3621770PMC
February 2013

RET fusion genes in non-small-cell lung cancer.

J Clin Oncol 2012 Dec 13;30(35):4439-41. Epub 2012 Nov 13.

The Ohio State University, Columbus, OH, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2012.45.8240
Publisher Site
http://dx.doi.org/10.1200/JCO.2012.45.8240DOI Listing
December 2012

HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib.

Oncology 2012 15;82(3):175-9. Epub 2012 Mar 15.

The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA.

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/336488
Publisher Site
http://dx.doi.org/10.1159/000336488DOI Listing
June 2012

The search for an optimal DNA, RNA, and protein detection by in situ hybridization, immunohistochemistry, and solution-based methods.

Methods 2010 Dec 1;52(4):281-6. Epub 2010 Oct 1.

Divisions of Hematology & Medical Oncology, Department of Internal Medicine, Comprehensive Cancer Center, College of Medicine, The Ohio State University, 320 West 10th Avenue, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ymeth.2010.09.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3375896PMC
December 2010

A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies.

Cancer Chemother Pharmacol 2010 Apr 6;65(5):863-9. Epub 2009 Aug 6.

The Ohio State University Comprehensive Cancer Center, B407 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-009-1091-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261191PMC
April 2010

Malignant thymoma with immunodeficiency (Good syndrome) associated with mucormycosis.

Am J Clin Oncol 2010 Feb;33(1):109

Division of Hematology and Oncology, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV 26506, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0b013e31802c5430DOI Listing
February 2010

Lung specific expression of a human mutant p53 affects cell proliferation in transgenic mice.

Transgenic Res 2008 Jun 30;17(3):355-66. Epub 2007 Oct 30.

Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University College of Medicine and Public Health, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11248-007-9154-3DOI Listing
June 2008

Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.

Cancer Chemother Pharmacol 2007 Jan 10;59(1):23-33. Epub 2006 May 10.

Department of Medicine, The Ohio State University College of Medicine and Public Health, B406 Starling-Loving Hall, 320 West 10th Avenue, Columbus, OH, 43210-1240, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-006-0249-yDOI Listing
January 2007

Incorporation of photodynamic therapy as an induction modality in non-small cell lung cancer.

Lasers Surg Med 2006 Dec;38(10):881-9

The Ohio State University Medical Center, Division of Cardiothoracic Surgery, Columbus, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/lsm.20444DOI Listing
December 2006

A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma.

BMC Cancer 2006 Dec 6;6:278. Epub 2006 Dec 6.

Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-6-278DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1712353PMC
December 2006

Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells.

Exp Cell Res 2006 Oct 21;312(17):3370-8. Epub 2006 Jul 21.

Comprehensive Cancer Center and Department of Internal Medicine at The Ohio State University College of Medicine and Public Health, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S001448270600277
Publisher Site
http://dx.doi.org/10.1016/j.yexcr.2006.07.005DOI Listing
October 2006

Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development.

Pharm Res 2006 Jun 25;23(6):1265-74. Epub 2006 May 25.

College of Pharmacy, The Ohio State University, 496 West 12th Avenue, Columbus, Ohio 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11095-006-0165-1DOI Listing
June 2006

Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer.

Clin Breast Cancer 2006 Jun;7(2):141-5

Division of Hematology and Oncology, Comprehensive Cancer Center, Ohio State University Medical Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2006.n.023DOI Listing
June 2006

Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients.

J Clin Oncol 2006 Apr;24(12):1852-9

Division of Hematology/Oncology, Department of Internal Medicine and Center for Biostatistics, The Ohio State University College of Medicine and Public Health, Columbus, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.04.2838DOI Listing
April 2006

Preclinical experience with docetaxel in gastrointestinal cancers.

Semin Oncol 2005 Apr;32(2 Suppl 4):S3-9

Department of Medicine at The Ohio State University College of Medicine and Public Health, Columbus 43210-1240, USA.

View Article

Download full-text PDF

Source
April 2005

Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer.

Clin Cancer Res 2005 Mar;11(5):1870-6

Division of Hematology/Oncology, Arthur G. James Cancer Hospital, Ohio State University, 320 West Tenth Avenue, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-04-1727DOI Listing
March 2005

Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer.

J Natl Cancer Inst 2004 Nov;96(22):1718-21

Comprehensive Cancer Center and Department of Internal Medicine, The Ohio State University College of Medicine and Public Health, Columbus 43210-1240, USA.

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/96/22/1718.full.pdf
Web Search
http://jnci.oxfordjournals.org/cgi/doi/10.1093/jnci/djh292
Publisher Site
http://dx.doi.org/10.1093/jnci/djh292DOI Listing
November 2004

5-aza-2'-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation.

J Biol Chem 2004 Apr 13;279(15):15161-6. Epub 2004 Jan 13.

Department of Biochemistry and Molecular Biology, University of Health Science Center, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M311703200DOI Listing
April 2004

Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.

Clin Cancer Res 2003 Aug;9(9):3303-11

Department of Medicine and College of Pharmacy, The Ohio State University, The Arthur G James Cancer Hospital & Richard J Solove Research Institute, Columbus, Ohio 43210-1240, USA.

View Article

Download full-text PDF

Source
August 2003

P21 response to DNA damage induced by genistein and etoposide in human lung cancer cells.

Biochem Biophys Res Commun 2003 Jun;305(4):950-6

Arthur James Cancer Hospital and Richard Solove Research Institute, Comprehensive Cancer Center, and Department of Internal Medicine, The Ohio State University, Columbus, OH 43210-1240, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0006-291x(03)00873-8DOI Listing
June 2003

Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter.

Mol Cell Biol 2003 Jun;23(12):4056-65

Department of Internal Medicine. Department of Pathology, The Ohio State University-Comprehensive Cancer Center, Columbus, Ohio 43210, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC156121PMC
http://dx.doi.org/10.1128/mcb.23.12.4056-4065.2003DOI Listing
June 2003

Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice.

Oncogene 2002 Nov;21(51):7831-8

Comprehensive Cancer Center, The Ohio State University College of Medicine and Public Health, Columbus, Ohio, OH 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1205909DOI Listing
November 2002

Mitomycin as a modulator of irinotecan anticancer activity.

Oncology (Williston Park) 2002 Aug;16(8 Suppl 7):21-5

Department of Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, USA.

View Article

Download full-text PDF

Source
August 2002

Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies.

J Clin Oncol 2002 Jun;20(11):2616-23

Department of Medicine, Ohio State University College of Medicine and Public Health, Columbus, OH 43210-1240, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2002.22.030DOI Listing
June 2002

A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.

Clin Cancer Res 2002 Jan;8(1):75-85

Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, 78229, USA.

View Article

Download full-text PDF

Source
January 2002

Taxanes and capecitabine in combination: rationale and clinical results.

Clin Breast Cancer 2002 Jan;2(4):287-93

Department of Medicine, Arthur G. James Cancer Hospital, Richard J. Solove Research Institute, Ohio State University, B406 Starling-Loving Hall, 320 West 10th Avenue, Columbus, OH 43210-1240, USA.

View Article

Download full-text PDF

Source
January 2002